DK1634498T3 - Exo-S-mecamylamine formulation - Google Patents
Exo-S-mecamylamine formulationInfo
- Publication number
- DK1634498T3 DK1634498T3 DK05024899T DK05024899T DK1634498T3 DK 1634498 T3 DK1634498 T3 DK 1634498T3 DK 05024899 T DK05024899 T DK 05024899T DK 05024899 T DK05024899 T DK 05024899T DK 1634498 T3 DK1634498 T3 DK 1634498T3
- Authority
- DK
- Denmark
- Prior art keywords
- exo
- mecamylamine
- pharmaceutically acceptable
- disorder
- amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11253498P | 1998-12-16 | 1998-12-16 | |
PCT/US1999/030137 WO2000035280A1 (en) | 1998-12-16 | 1999-12-16 | Exo-r-mecamylamine formulation and use in treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1634498T3 true DK1634498T3 (da) | 2008-12-15 |
Family
ID=22344414
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05024899T DK1634498T3 (da) | 1998-12-16 | 1999-12-16 | Exo-S-mecamylamine formulation |
DK99967401T DK1139743T3 (da) | 1998-12-16 | 1999-12-16 | Exo-S-mecamylaminformulering og anvendelse heraf i behandlinger |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK99967401T DK1139743T3 (da) | 1998-12-16 | 1999-12-16 | Exo-S-mecamylaminformulering og anvendelse heraf i behandlinger |
Country Status (12)
Country | Link |
---|---|
US (1) | US20020016370A1 (da) |
EP (3) | EP1139743B1 (da) |
JP (5) | JP2002532392A (da) |
AT (2) | ATE406797T1 (da) |
AU (2) | AU2368200A (da) |
CA (2) | CA2393437C (da) |
CY (1) | CY1108577T1 (da) |
DE (2) | DE69930552T2 (da) |
DK (2) | DK1634498T3 (da) |
ES (2) | ES2260959T3 (da) |
PT (2) | PT1634498E (da) |
WO (2) | WO2000035280A1 (da) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE521512C2 (sv) | 2001-06-25 | 2003-11-11 | Niconovum Ab | Anordning för administrering av en substans till främre delen av en individs munhåla |
US7045534B2 (en) | 2002-02-12 | 2006-05-16 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of reducing angiogenesis |
SI1578422T1 (sl) | 2002-12-20 | 2007-12-31 | Niconovum Ab | Fizikalno in kemiäśno stabilni nikotin in mikrokristal na celulozo vsebujoäś material iz trdnih delcev |
DK1603544T3 (da) * | 2003-03-14 | 2008-01-14 | Agi Therapeutics Res Ltd | Behandling af intestinale tilstande med N-2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amin |
US20070224284A1 (en) * | 2004-03-12 | 2007-09-27 | John Devane | Methods and compositions comprising at least one alpha3 beta4 nAChR antagonist or pharmaceutically acceptable salt thereof |
DE10318714B4 (de) * | 2003-04-25 | 2006-03-23 | Hf Arzneimittelforschung Gmbh | Wirkstoff-Kombinationen und Therapien zur Bekämpfung des Alkoholmissbrauches |
CA2580329C (en) | 2004-09-13 | 2015-01-06 | Chrono Therapeutics Inc. | Biosynchronous transdermal drug delivery |
US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
JP2009519962A (ja) * | 2005-12-19 | 2009-05-21 | コメンティス,インコーポレーテッド | 眼投与用局所メカミルアミン製剤およびその使用 |
AU2007224584A1 (en) | 2006-03-16 | 2007-09-20 | Niconovum Ab | Improved snuff composition |
MX2009003845A (es) * | 2006-10-09 | 2009-04-23 | Smithkline Beecham Corp | Composiciones para reducir los sintomas de abstinencia de nicotina y/o el uso del tabaco. |
US20080242948A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Effective low-profile health monitoring or the like |
US20080243005A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
US20090005653A1 (en) * | 2007-03-30 | 2009-01-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
US20090018407A1 (en) * | 2007-03-30 | 2009-01-15 | Searete Llc, A Limited Corporation Of The State Of Delaware | Computational user-health testing |
US20080242949A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
US20090119154A1 (en) * | 2007-11-07 | 2009-05-07 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Determining a demographic characteristic based on computational user-health testing of a user interaction with advertiser-specified content |
US20080319276A1 (en) * | 2007-03-30 | 2008-12-25 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
US20080242951A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Effective low-profile health monitoring or the like |
US20080242952A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liablity Corporation Of The State Of Delaware | Effective response protocols for health monitoring or the like |
US20090005654A1 (en) * | 2007-03-30 | 2009-01-01 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Computational user-health testing |
US20080242947A1 (en) * | 2007-03-30 | 2008-10-02 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Configuring software for effective health monitoring or the like |
EP2322167A1 (en) * | 2007-04-02 | 2011-05-18 | Parkinson's Institute | Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments |
US8569381B2 (en) | 2008-05-23 | 2013-10-29 | Targacept, Inc. | Combination therapy for the management of hypertension |
AT507187B1 (de) * | 2008-10-23 | 2010-03-15 | Helmut Dr Buchberger | Inhalator |
SG176766A1 (en) * | 2009-07-14 | 2012-01-30 | Targacept Inc | Exo-s-mecamylamine method, use, and compound for treatment |
JO3250B1 (ar) | 2009-09-22 | 2018-09-16 | Novartis Ag | إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7 |
MX337106B (es) * | 2010-05-27 | 2016-02-12 | Targacept Inc | Antagonistas no competitivos de receptores nicotinicos. |
WO2012106739A1 (de) | 2011-02-11 | 2012-08-16 | Helmut Buchberger | Inhalatorkomponente |
AT510837B1 (de) | 2011-07-27 | 2012-07-15 | Helmut Dr Buchberger | Inhalatorkomponente |
WO2013006643A1 (en) | 2011-07-06 | 2013-01-10 | The Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
RU2636649C9 (ru) | 2011-09-06 | 2018-04-06 | Бритиш Америкэн Тобэкко (Инвестментс) Лимитед | Устройство и способ нагревания курительного материала |
JP5808490B2 (ja) | 2011-09-06 | 2015-11-10 | ブリティッシュ アメリカン タバコ (インヴェストメンツ) リミテッドBritish Americantobacco (Investments) Limited | 喫煙材の加熱 |
AT511344B1 (de) | 2011-10-21 | 2012-11-15 | Helmut Dr Buchberger | Inhalatorkomponente |
US8901177B2 (en) * | 2012-03-23 | 2014-12-02 | Targacept, Inc. | Method of treating bladder disorders |
GB201207039D0 (en) | 2012-04-23 | 2012-06-06 | British American Tobacco Co | Heating smokeable material |
GB2504076A (en) | 2012-07-16 | 2014-01-22 | Nicoventures Holdings Ltd | Electronic smoking device |
GB2513637A (en) | 2013-05-02 | 2014-11-05 | Nicoventures Holdings Ltd | Electronic cigarette |
GB2513639A (en) | 2013-05-02 | 2014-11-05 | Nicoventures Holdings Ltd | Electronic cigarette |
GB2514893B (en) | 2013-06-04 | 2017-12-06 | Nicoventures Holdings Ltd | Container |
GB201407426D0 (en) | 2014-04-28 | 2014-06-11 | Batmark Ltd | Aerosol forming component |
GB2528673B (en) | 2014-07-25 | 2020-07-01 | Nicoventures Holdings Ltd | Aerosol provision system |
JP6682533B2 (ja) * | 2014-08-22 | 2020-04-15 | アタカマ セラピューティクス,インコーポレーテッド | 多汗症を治療するための方法 |
GB2533135B (en) | 2014-12-11 | 2020-11-11 | Nicoventures Holdings Ltd | Aerosol provision systems |
AU2016211330A1 (en) | 2015-01-28 | 2017-08-03 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
WO2016145373A1 (en) | 2015-03-12 | 2016-09-15 | Chrono Therapeutics Inc. | Craving input and support system |
GB201511349D0 (en) | 2015-06-29 | 2015-08-12 | Nicoventures Holdings Ltd | Electronic aerosol provision systems |
US11924930B2 (en) | 2015-08-31 | 2024-03-05 | Nicoventures Trading Limited | Article for use with apparatus for heating smokable material |
US20170055584A1 (en) | 2015-08-31 | 2017-03-02 | British American Tobacco (Investments) Limited | Article for use with apparatus for heating smokable material |
US20170119046A1 (en) | 2015-10-30 | 2017-05-04 | British American Tobacco (Investments) Limited | Apparatus for Heating Smokable Material |
BR112018071824B1 (pt) | 2016-04-27 | 2023-01-10 | Nicoventures Trading Limited | Subconjunto, sistema, método para fabricar um vaporizador e dispositivo de fornecimento de vapor eletrônico |
EP3565617A1 (en) | 2017-01-06 | 2019-11-13 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
US11596779B2 (en) | 2018-05-29 | 2023-03-07 | Morningside Venture Investments Limited | Drug delivery methods and systems |
GB202203728D0 (en) * | 2022-03-17 | 2022-05-04 | Univ Oxford Innovation Ltd | Treatments and methods for increasing dopamine |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5039801A (en) * | 1985-12-20 | 1991-08-13 | The United States Of America As Represented By The Department Of Health & Human Services | Thermal fragmentation of methylbenzylurea disastereomers or secondary amines and preparation of optically active secondary amines |
US4749686A (en) * | 1986-12-04 | 1988-06-07 | New York Medical College | Combinations of renal vasodilators and α1 -adrenergic or ganglionic blocking agents and methods for treating diseases |
EP0302595B1 (en) * | 1987-07-07 | 1994-02-02 | Beecham Group Plc | Pinacidil for treatment of pulmonary hypertension or right heart failure |
US5691365A (en) * | 1995-07-18 | 1997-11-25 | University Of Kentucky Research Foundation | Nicotinic receptor antagonists in the treatment of neuropharmacological disorders |
-
1999
- 1999-12-16 PT PT05024899T patent/PT1634498E/pt unknown
- 1999-12-16 JP JP2000587608A patent/JP2002532392A/ja active Pending
- 1999-12-16 JP JP2000587609A patent/JP2002532393A/ja not_active Withdrawn
- 1999-12-16 ES ES99967401T patent/ES2260959T3/es not_active Expired - Lifetime
- 1999-12-16 AU AU23682/00A patent/AU2368200A/en not_active Abandoned
- 1999-12-16 DE DE69930552T patent/DE69930552T2/de not_active Expired - Lifetime
- 1999-12-16 WO PCT/US1999/030137 patent/WO2000035280A1/en not_active Application Discontinuation
- 1999-12-16 EP EP99967401A patent/EP1139743B1/en not_active Expired - Lifetime
- 1999-12-16 EP EP99967396A patent/EP1139744A4/en not_active Withdrawn
- 1999-12-16 AT AT05024899T patent/ATE406797T1/de active
- 1999-12-16 DK DK05024899T patent/DK1634498T3/da active
- 1999-12-16 PT PT99967401T patent/PT1139743E/pt unknown
- 1999-12-16 CA CA002393437A patent/CA2393437C/en not_active Expired - Fee Related
- 1999-12-16 WO PCT/US1999/030153 patent/WO2000035279A1/en active IP Right Grant
- 1999-12-16 CA CA002393442A patent/CA2393442A1/en not_active Abandoned
- 1999-12-16 AU AU23686/00A patent/AU2368600A/en not_active Abandoned
- 1999-12-16 DK DK99967401T patent/DK1139743T3/da active
- 1999-12-16 DE DE69939498T patent/DE69939498D1/de not_active Expired - Lifetime
- 1999-12-16 AT AT99967401T patent/ATE320711T1/de active
- 1999-12-16 ES ES05024899T patent/ES2313187T3/es not_active Expired - Lifetime
- 1999-12-16 EP EP05024899A patent/EP1634498B1/en not_active Expired - Lifetime
-
2001
- 2001-06-15 US US09/882,934 patent/US20020016370A1/en not_active Abandoned
-
2008
- 2008-11-19 CY CY20081101333T patent/CY1108577T1/el unknown
-
2011
- 2011-03-14 JP JP2011055716A patent/JP2011126909A/ja not_active Withdrawn
-
2013
- 2013-12-13 JP JP2013258032A patent/JP2014051528A/ja active Pending
-
2016
- 2016-01-25 JP JP2016011658A patent/JP2016065108A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20020016370A1 (en) | 2002-02-07 |
EP1139743A4 (en) | 2003-01-02 |
EP1139744A4 (en) | 2003-01-02 |
CA2393437C (en) | 2009-12-15 |
EP1634498A3 (en) | 2006-03-29 |
PT1634498E (pt) | 2008-10-28 |
PT1139743E (pt) | 2006-06-30 |
DE69930552T2 (de) | 2006-11-30 |
EP1139743B1 (en) | 2006-03-22 |
CA2393442A1 (en) | 2000-06-22 |
DE69930552D1 (de) | 2006-05-11 |
ES2260959T3 (es) | 2006-11-01 |
WO2000035280A1 (en) | 2000-06-22 |
JP2016065108A (ja) | 2016-04-28 |
ES2313187T3 (es) | 2009-03-01 |
JP2002532392A (ja) | 2002-10-02 |
JP2014051528A (ja) | 2014-03-20 |
CA2393437A1 (en) | 2000-06-22 |
EP1634498A2 (en) | 2006-03-15 |
EP1139743A1 (en) | 2001-10-10 |
EP1139744A1 (en) | 2001-10-10 |
JP2011126909A (ja) | 2011-06-30 |
DK1139743T3 (da) | 2006-07-31 |
WO2000035279A1 (en) | 2000-06-22 |
ATE406797T1 (de) | 2008-09-15 |
CY1108577T1 (el) | 2014-04-09 |
DE69939498D1 (de) | 2008-10-16 |
ATE320711T1 (de) | 2006-04-15 |
JP2002532393A (ja) | 2002-10-02 |
EP1634498B1 (en) | 2008-09-03 |
AU2368600A (en) | 2000-07-03 |
AU2368200A (en) | 2000-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE406797T1 (de) | Exo-s-mecamylamin-formulierung | |
PT740650E (pt) | Co-farmacos como um metodo de administracao controlada de farmacos | |
BR0206559A (pt) | Uso de um composto, método de tratamento ou prevenção de disfunções, uso ou método, método de neuroproteção e composto | |
ATE253039T1 (de) | Beta 2 -adrenergische rezeptor-agonisten | |
WO2002043652A3 (en) | Anti-proliferative drugs | |
JP2002532392A5 (da) | ||
Summers et al. | THA—a review of the literature and its use in treatment of five overdose patients | |
MX348062B (es) | Mutantes que degradan proteoglicanos para tratamiento del snc. | |
ATE433959T1 (de) | Analoge von kokain | |
TW200607511A (en) | Use of optically pure (S,S)-reboxetine in the manufacture of a medicament for the treatment or prevention of peripheral neuropathy | |
BG103521A (en) | Substituted pyrimidinon and pyridon compounds and methods for their application | |
DK1212060T3 (da) | Anvendelse af nikotin eller derivater heraf samt L-DOPA i et lægemiddel til behandling af neurologiske sygdomme, især Parkinsons sygdom | |
Sun et al. | Management of tetanus: a review of 18 cases | |
NO317485B1 (no) | Fremgangsmate for fremstilling av ZME-018 gelonin immunokonjugat for behandling av melanom | |
ES2187646T3 (es) | Procedimientos para el tratamiento de inflamaciones y composiciones correspondientes. | |
Feinberg et al. | Methadone and schizophrenia. | |
GR3001420T3 (en) | Prazosin-pirbuterol combination for bronchodilation | |
Mison-Crighel et al. | Glutaminase activity and neocortical excitability | |
NZ224502A (en) | Silyl alkylene amines and pharmaceutical use, methods for preparation and the treatment of non humans | |
Booij | The history of neuromuscular blocking agents | |
CA2511664A1 (en) | 4',4''-substituted 3.alpha.-(diphenylmethoxy)tropane analogs for treatment of mental disorders | |
KR100403722B1 (en) | Lower alcohol insoluble extract of hovenia dulcis thunberg having liver protection activity, polysaccharide separated therefrom and composition containing the same | |
Messer et al. | Synthesis, biochemical activity and behavioral effects of a series of 1, 4, 5, 6-tetrahydropyrimidines as novel ligands for M1 receptors | |
KR920000717A (ko) | 디클로로아닐린 화합물 | |
Ajit et al. | Illicit Drugs and their Assessment: A Brief Review |